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1-ES-01-1 Pharmacology Education:
Current Status and Future Perspective
Haruaki Nakaya
Chiba University
Looking back on pharmacology education for the last several
decades, the number of drugs, described in the textbook of
pharmacology, may have been increased by more than ten
times. For students at schools of medicine, pharmacy, den-
tistry and veterinary medicine, medical knowledge to be un-
derstood in not only pharmacology but also in other related
fields such as physiology and biochemistry are increasing
year by year. Therefore, it is impossible for the students to
remember the pharmacological properties and side effects of
all the drugs used in Japan any more. The only thing that
they can do may be learning how each drug produces the effi-
cacy in the pathophysiological state of variable disease. Prob-
lem based learning (PBL) may be useful for combined under-
standing of pathophysiology and pharmacology. In the future,
molecularly targeted drugs including antibody drugs may be
increased and understanding of pathophysiology of variable
diseases may become more important in pharmacology educa-
tion. We have to teach the students mainly the way by which
drugs exert their effectiveness and side effects rather than
the name of drugs.
1-ES-01-3 Pharmacology in clinical
practice from the viewpoint of a dentist
Shinji Iizuka
Iizuka Dental Clinic
While dental treatment centers on surgical procedures, treat-
ment for infectious diseases in the maxillofacial area and the
removal of pain use antibiotic agents, antipyretic analgesics,
and local anesthetic agents. With the progress of preventive
treatment, dental treatment is changing now with fewer pedi-
atric caries and more remaining teeth in elderly patients.
Therefore, the age group in need of dental treatment mainly
consists of middle-aged adults and the elderly. The majority
of them have underlying diseases other than odontopathy, and
take prescription medication unrelated to dentistry. The time
when all dentists had to do was treat diseases unique to den-
tistry is gone, and even general dental practitioners must
provide treatment in response to the general physical condi-
tions of patients with some kind of underlying conditions. For
this purpose, I think that not only dentists but hygienists need
to acquire pharmacological knowledge, such as interactions
between routine medications and medications prescribed by
a dentist, and unpleasant symptoms or side effects appearing
inside the mouth caused by routine medications.S1-ES-01-2 Pharmacology in clinical
practice from the viewpoint of a doctor
Yoshioki Satoh
Yamanashi Rehabilitation Hospital
The crisis in 2025, when baby-boomers will become 75 years
old or older, has been raised as a social issue. Thus the bur-
den on clinical practice increases each day with the rapid
growth of the elderly population, a wide variety of diseases,
and specialized and advanced medicine. An enormous range
of categories of drugs currently exist compared with 30 years
ago when I studied pharmacology. It is very difficult to up-
date one’s knowledge of drugs beyond one’s area of expertise,
resulting in the treatment of patients amid a glut of biased in-
formation. One overwhelming difference between clinical
practice and university lectures is that patients may suffer
multiple diseases, as well as having their own personal back-
ground and individual problems. Therefore, what is expected
of doctors is not only medical knowledge of diseases but the
capability to organize knowledge and information on medical
insurance, nursing care insurance, and the social security
system and to cooperate with professionals in multiple fields.
The year 2025 will be a challenging year in pharmacology in
that knowledge of the effects and side effects of medications
needs to be absorbed, and at the same time, there will be a de-
mand for pharmacology which is linked to general medical
exams.
1-ES-01-4 Pharmacology in clinical
practice from the viewpoint of a
veterinarian
Takeo Ueda
Upfield Veterinary Hospital
In the last decades, veterinary medicine has been progressing
remarkably and drugs utilized have rapidly enlarged. On the
other hand, most veterinarians especially in primary care
need to prescribe quite wide range of drugs to some species
of animals with different metabolism. Therefore, one of chal-
lenges of veterinary pharmacology from now is how to learn
numerous drugs with metabolic characteristic of each ani-
mal. At the same time, understandings of side effects besides
their efficacy would be necessary in clinical practice. Sec-
ondly, as definitive diagnosis isn’t always obtained, diagnostic
treatment based on tentative diagnosis needs to be performed
in some cases. Then making a proper treatment plan would
conduce to suitable choices of drugs. Thus, training and ac-
quirement of planning capability would be important for
proper medical usage. Finally, animal welfare is recently em-
phasized and will be more in the future. From the pharma-
cological point of view, analgesics and sedatives could con-
tribute to this purpose because they can reduce pain and fear.
As these medicines don’t appear to be used enough now, some
more efforts would need to be put to make substantial use of
them in veterinary pharmacology.8
1-ES-01-5 Pharmacology in clinical
practice from the viewpoint of a
pharmacist
Kazuhiro Matsuo
Dept. of Clin. Pharm., Faculty of Pharm. Sci., Toho Univ.
About 20 years ago when I was a university student, pharma-
codynamics was an essential part of pharmacology. Then,
pharmacists working in hospitals relied on their knowledge
of pharmacodynamics to ensure that drugs were properly ad-
ministered. Now, however, in addition to duties such as com-
pounding medicines, they must also work directly with pa-
tients under their care. As a result, knowledge of pharma-
cokinetics and pharmacogenetics has become more impor-
tant, since the hospital pharmacists must also pay attention to
the patient’s individual needs. More and more, pharmacists
are playing an important role in clinical practices including
medical security to prevent serious medical accidents caused
by improper administration of drugs. They are also becom-
ing involved in the planning of regional medicine (making of
health support drugstore (tentative name)). So, because phar-
macists are medical professionals who have specialized
knowledge of drugs, they should take responsibilities for all
kinds of medicines using every aspect of our knowledge of
pharmacology.
3-ES-01-2 Changes in the prevalence of
new psychoactive substances and their
legal status
Ruri Kikura Hanajiri
National Institute of Health Sciences
A wide variety of new psychoactive substances (NPSs) has
emerged around the world over the past fifteen years. To
counter the spread of these NPSs, the Pharmaceutical Affairs
Law in Japan was amended in 2006 to establish a new cate-
gory, Designated Substances in order to more promptly con-
trol the NPSs. However, as quickly as they were controlled,
other analogs of the controlled substances began to appear on
the illegal drug market, and the identification and control of
these substances rapidly developed into a cat and mouse
game. An alarming increase in emergency hospitalizations
caused by products containing various analogs of synthetic
cannabinoids and/or cathinone derivatives has been observed
since 2011. Moreover, several fatalities related to these prod-
ucts have occurred, and car accidents caused by impaired
consciousness after smoking the products have been a serious
problem since 2012. After the serious car accident related to
NPSs in Ikebukuro in June, 2014, the regulation and control of
the NPSs has been particularly strengthened and the emer-
gence and distribution of the NPSs has dramatically de-
creased. In this educational seminar, changes in the preva-
lence of NPSs and their legal status, based on our survey for
13 years, will be shown.S3-ES-01-1 New psychoactive
substances and dependence producing
drugs
Tsutomu Suzuki
Drug Depend. Lab., Hoshi Univ. Sch. Pharm.
In recent year, the abuse of new psychotropic substances
(NPSs) becomes a big social problem. However, there is very
little scientific information concerning NPSs. On the other
hand, the world health organization (WHO) indicated that
there are 9 different types of psychoactive dependence pro-
ducing drug, each of which produces a characteristic, dose
related, clinical syndrome. Under certain circumstances of
use, each will produce some degree of psychological depend-
ence, physical dependence and tolerance may or may not be
present, depending on the type of drug. In the present sympo-
sium, I introduce 9 different types of psychoactive depend-
ence producing drug, such as cannabis, cocaine, hallucino-
gen, opioid etc., and then I discuss the similarity of the classi-
cal psychoactive dependence producing drugs and NPSs.
3-ES-01-3 The harmful effects of law
evading drugs: their identities explored
from pharmacological research
Masahiko Funada, Ken ichi Tomiyama
Dept. Drug Dependence Res., NIMH, NCNP
Most law evading herbal products consist of finely chopped,
dry vegetative matter mixed with chemical substances.
Analysis of chemical substances in herbal products clarified
that they contain synthetic cannabinoids. We established a
psychic dependence liability and cytotoxicity screening sys-
tem for synthetic cannabinoids using animals and cell cul-
tures. Synthetic cannabinoids produced the rewarding ef-
fects. The rewarding effects of synthetic cannabinoids were
completely suppressed by cannabinoid CB1 receptor antago-
nist. CB1 receptor might be involved in the expression of syn-
thetic cannabinoid induced rewarding effect. Furthermore,
treatment with synthetic cannabinoid in striatal primary cul-
ture caused cell death. These behavioral and neurochemical
data indicate that synthetic cannabinoids may have a psy-
chic dependence liability and has strong neurotoxicity. With
our drug screening system, we were able to rapidly evaluate
and quantify psychic dependence liabilities and the cytotox-
icity of synthetic cannabinoids contained in law evading
herbal products. These scientific data using our screening
system contributed to the establishment of legislation for
comprehensive designations of synthetic cannabinoids.9
3-ES-02-1 Neurovascular interaction
during central nervous system
regeneration
Rieko Muramatsu 1,2, Toshihide Yamashita 1
1Dept. Mol. Neurosci. Grad. Sch. Med. Osaka Univ., 2 JST, PRESTO
Angiogenesis is a prominent feature of central nervous sys-
tem (CNS) pathology and is crucial for regulating disease pro-
gression. Although neuronal damage is a primary response
during CNS disease progression, the relevance of neuronal
damage in pathological angiogenesis is still unclear and the
key angiogenesis promoting factor(s) derived from damaged
cells remain to be identified. In this study, we show that de-
generating axons release lactate dehydrogenase A (LDHA),
known thus far only as a useful marker of pathology, drives
pathological angiogenesis around the lesion of experimental
autoimmune encephalomyelitis and controlled cortical im-
pact induced lesions. Extracellular LDHA mediated angio-
genesis was dependent on surface vimentin expression. Si-
lencing vimentin expression in vascular endothelial cells pre-
vented angiogenesis around EAE lesions and extended sur-
vival in a mouse model of glioblastoma.
3-ES-02-3 My CareerAs a Reviewer at
PMDA
Kinue Nishioka
PMDA
I work in the Pharmaceuticals and Medical Devices Agency
(PMDA). PMDA is the regulatory agency working together
with the Ministry of Health, Labor and Welfare (MHLW).
PMDA and MHLW are responsible for approval, post mar-
keting safety and relief services of pharmaceuticals and
medical devices. Pharmaceuticals include chemical, biologi-
cal, generic, and OTC drugs, cosmetics, etc. Review divisions
of PMDA consist of three areas : drugs, medical devices, and
cellular and tissue based products. Now, I am reviewing new
medical drugs for metabolic disorders and endocrine disor-
ders from chronic diseases such as diabetes or osteoporosis to
rare diseases such as inherited metabolic disease. Moreover I
am involved in the ICH Implementation Working Group ac-
tivities. I joined PMDA as an experienced employee and I
would like to introduce my experience as not only a reviewer
but also a researcher in my previous career. I hope my pres-
entation helps give direction to undecided young researchers.S13-ES-02-2 AWork Life Balance in
Academic Career
Mika Takarada
Dept. Neuroanat., Grad. Sch. Med. Sci., Kanazawa Univ.
What is the best way to balance family life and successful ca-
reer in the academia? There is no answer and no rules about
how to achieve this. The important thing is, “the lack of role
models” is one of the key barriers to decide one’s career, es-
pecially for women. Today, I’d like to tell you my career path
as a case in the academia. I also provide a brief introduction
of my research and important events in my life, and the way
how I combine research with motherhood. I completed my
bachelor’s, master’s and doctoral degree in the faculty of
pharmacy at the Kanazawa University. Then I joined the fac-
ulty of medicine at the Kanazawa University as an assistant
professor in the department of neuroanatomy. My research
focuses on understanding the development of various brain
pathologies by focusing on glial cells that maintain the homeo-
stasis in the central nervous system using animal models. To
maintain a balance between research and family life, there
are lots of things have helped me : support system of univer-
sity, childcare support, supportive colleagues, partner and
family. I hope my experience could serve as one role model
for young researchers.
3-ES-02-4 career paths as a corporate
researcher in Shiseido
Kentaro Kajiya
Shiseido Research Center
Shiseido has long focused on basic research in skin biology in
collaboration with domestic as well as foreign universities. I
am going to talk about career paths as an example of my ca-
reer in Shiseido including studying abroad. Based on the find-
ings in basic research in skin, I had been also engaged in the
launch of a new cosmetic brand. It would be great if a corpo-
rate researcher could be one choice for people joining in this
seminar.0
3-ES-02-5 How establishing a foreign
network will improve your career!
Naoki Kojima
Pharmacology 2, Taisho Pharmaceutical Co., Ltd.
The ultimate goal of biomedical researcher at pharmaceuti-
cal company is to develop a novel therapy that relieves the
symptoms of diseases from patients. In order to accomplish
this goal, the researcher should be willing to try innovative
strategies or to learn novel techniques to broaden their scien-
tific thinking.
In pharmaceutical company, there are several research steps
starting with discovering new chemical entities into obtain-
ing regulatory approval to market it. These are applied sci-
ence based on a number of wisdoms and experiences. There-
fore, lots of experiences through multiple ways must be ne-
cessity for one’s own development.
Performing research at a foreign research institution is one
of the best ways to expand one’s scientific thinking. It is high
priority to establish a resourceful network with world re-
nown researchers in the biomedical field. While their way of
thinking maybe different, it is creative and gives you a
chance to discuss and to adjust your own ideas. Establishing a
relationship or collaboration will serve as a valuable asset for
your career. Another benefit is that you will know if your
own research is globally accepted. Additionally, it may be an
effective way to compare your scientific philosophy with oth-
ers in a different environment.
3-ES-02-7 Academic Research Career in
the US
Yasuko Iwakiri
Dept. Int Med (Digestive Diseases), Yale Univ. Sch. Med.
I received BS degree in Japan and moved to the US to attend
graduate school. After receiving Master degree in nutritional
biochemistry in 1995 from Oregon State University, I moved
to Colorado State University, where I received PhD degree in
nutritional biochemistry in 2000. To obtain postdoc training, I
came to Yale. 6 years after the postdoc training, I was pro-
moted to Assistant Professor in 2006, then to Associate pro-
fessor in 2012. My lab focuses on understanding how hemody-
namic changes influence liver function and structure and de-
veloping new therapy to treat liver fibrosis and portal hyper-
tension (a serious complication in liver diseases). I currently
serve as an associate editor in Hepatology and an editorial
board member in Journal of Hepatology and Hepatology In-
ternational.
I would like to talk about being a principle investigator and
having lab in universities in the US.S3-ES-02-6 There’s SomethingAbout
Vascular Biology
Hiroyasu Kidoya
Dept. of Signal Transduction, RIMD, Osaka University
I received a doctor’s degree in 2008 and I’ve been working at
Osaka University as an associate professor after one year ex-
perience of post doctoral fellow. My major is vascular biology
and I’m researching in a wide viewpoint as developmental
analysis with the mouse model, or pathological analysis about
cancer and so on.
I’m a researcher, and a father of two as well. In my policy, I
want keep the balance of the three positions as a researcher,
father and myself to enjoy lifetime.
In this session, I would like to talk about life of a male re-
searcher at university through my own experience and how
marriage and child care influence to form the career.
1-PCE-1 The Objectives and
Approaches of RCR (Responsible of
Conduct of Research) Education
Jun Fudano
University Management Center, Tokyo Inst. of Tech.
What should be achieved through RCR education? And
How?While the new guideline set by the Ministry of Educa-
tion (MEXT) requires all research institutes including uni-
versities and colleges to provide research ethics education/
training for their members who are involved in research ac-
tivities, it seems that there are some confusion and miscon-
ception with regard to the objectives of such education/train-
ing. The instructions in the “preventive ethics” approach
which emphasize what sort of conducts are ”bad” and should
be avoided are quite common.In this presentation, the educa-
tional objectives of RCR instructions which were identified
by the Office of Research Integrity of the Department of
Health and Human Services (HHS) in the US are introduced.
A number of educational methods to achieve those objectives
are also discussed and illustrated by some concrete examples.
The author also claims that the preventive ethics mode of
RCR education should be complimented by the ”aspirational
ethics” approach in which what researchers can and should
do for the well-being of the public.11
1-PCE-2 The social impact of scientific
fraud
Ryoju Miwa
Miwa Ryoju Law Office
I will talk about the following topics.
1. Moral and Law related to scientific flaud
2. The social impact of both scientific fraud and lack of re-
search in Pharmacology
3. Retrospective and prospective view of lack of research
4. Upcoming super-aging society and expectations on The
Japanese Pharmacological Society
1-PCE-4 Initiative to prevent the
scientific publication misconduct in
Journal of Pharmacological Sciences
Kohji Fukunaga
Dept. Pharmacol., Tohoku Univ. Grad. Sch. Pharm. Sci.
Journal of Pharmacological Sciences (JPS) has been published
by the Japanese Pharmacological Society as pure reviewed
open access journal from Elsevier. To avoid the scientific
publication misconduct (fabrication, falsification, and plagia-
rism), the submitted papers were subjected to CrossCheck
before reviewing process. We also discuss the penalty and
check the truth the publication misconduct under criticism
from the readers after publication. The ethics committee
members in Japanese Pharmacological Society make another
efforts to define the scientific misconduct and to spread the
ethical education according to guideline for prevention of sci-
entific misconduct established by Ministry of Education, Cul-
ture, Sports, Science and Technology, Japan (http : //www.
mext.go.jp/b_menu/houdou/26/08/1351568.htm). In the sym-
posium, we introduce and discuss the initiative of JPS edito-
rial members to avoid the publication misconduct by showing
examples of the scientific publication misconduct in JPS.S11-PCE-3 Government measures about
clinical research
Reiko Mizutani
Office of Clinical Trial Promotion, Research and Development Division, Health
Policy Bureau, Ministry of Health, Labour and Welfare, Government of Japan
Since fiscal year 2013, improper incidents in clinical research
have been revealed one after another, which were recognized
as a social issue from the point of view of the reliability of re-
search results and the management of conflict of interest.
Later, the committee about the issue of improper incidents in
clinical research on hypertension medication was launched.
This committee compiled a report that recommended the dis-
cussion about the necessity of a revision of The Ethical
Guidelines for Clinical Research and the necessity of legal
framework that regulates clinical research. In addition, The
Healthcare Policy, approved by Cabinet on July 22, 2014,
mentioned that the rule system concerning clinical research
should be reviewed, including the consideration of the imple-
mentation of new legislation, in order to recover the public’s
reliance on clinical research in Japan. Based on these proce-
dures, The Ethical Guidelines for Medical and Health Re-
search Involving Human Subjects was compiled, promul-
gated on Dec. 22, 2014 and came into force on Apr. 1, 2015. In
addition, the committee about the rule system concerning
clinical research was launched and compiled a report. Based
on this report, new legislation is currently under considera-
tion.
1-PCE-5 Data management in clinical
trials:The Fact and the future
Naoki Matsumoto
Dept. Pharmacol., St. Marianna Univ. Sch. Med.
The data from clinical trials has some different features from
the basic researches. The basic researches are performed by
small number of researchers, but the clinical researches by
many persons not only by the researchers, but also ordinary
workers like clerks, nurses, and others. Especially notable
things are that the member includes those wishes to have re-
search data that ask doctors to gather data, and also the per-
sons those have to give themselves a data giver. These facts
means data management and quality assurance have to have
multiple points to be managed. As know from the several
scandals on the clinical trials in our nation, the present fact
might not be satisfactory, but the studies have to be con-
ducted today and in the future. The key to the bright future
might be the education of the wide variety of the party mem-
ber. These facts and possible future will be discussed in this
session.2
